Sold out94.75 KWD
Wegovy FlexTouch 2.4 mg is a prescription medication used for chronic weight management in adults with obesity or who are overweight and have at least one weight-related health condition. It contains semaglutide, a GLP-1 (glucagon-like peptide-1) analogue, and is administered as a once-weekly subcutaneous injection.
Semaglutide 3.2 mg/mL
Each pre-filled pen contains 9.6 mg semaglutide in 3 mL solution, delivering four weekly doses of 2.4 mg each.
Used as an adjunct to a reduced-calorie diet and increased physical activity for weight management in adults with:
Body Mass Index (BMI) ≥30 kg/m² (obesity)
BMI ≥27 kg/m² (overweight) with at least one weight-related comorbidity (such as hypertension, type 2 diabetes, or dyslipidemia)
Inject 2.4 mg subcutaneously once weekly, on the same day each week
Each FlexTouch pen contains four doses; use a new disposable needle for each injection
Injection sites: abdomen, thigh, or upper arm; rotate injection sites with each dose
The pen is compatible with NovoFine Plus, NovoFine, or NovoTwist disposable needles up to 8 mm in length
How It Works
Semaglutide mimics the action of GLP-1, a hormone that regulates appetite and food intake, helping to reduce hunger, improve satiety, and enhance control over eating behavior
Not recommended for individuals with a personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN 2)
Use with caution in patients with a history of pancreatitis, diabetic retinopathy, or severe gastrointestinal disease
Inform your doctor if you are taking other diabetes medications, as dose adjustments may be necessary
Nausea, vomiting, diarrhea, constipation, abdominal pain, headache
Side effects are most common at the start of treatment and usually decrease over time
Seek medical attention for severe or persistent symptoms
Store in a refrigerator (2°C–8°C). Do not freeze
After first use, the pen can be kept at room temperature (below 30°C) for up to 6 weeks
Keep out of reach of children
